Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer(ALTER0303) (ALTER0303)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT02388919 |
Recruitment Status :
Completed
First Posted : March 17, 2015
Last Update Posted : September 18, 2017
|
- Study Details
- Tabular View
- Results Submitted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Non-small Cell Lung Cancer | Drug: Anlotinib Drug: Placebo | Phase 2 Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 439 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | A Registered Randomized, Double-Blind, Placebo-Controlled (2:1), Multi-Centered Clinical Trial of Anlotinib as a Treatment for Advanced Non-Small Cell Lung Cancer |
Actual Study Start Date : | February 26, 2015 |
Actual Primary Completion Date : | January 5, 2017 |
Actual Study Completion Date : | January 6, 2017 |
Arm | Intervention/treatment |
---|---|
Experimental: Anlotinib
Anlotinib p.o, qd and it should be continued until disease progress or toxicity cannot be tolerated or patients withdraw consent
|
Drug: Anlotinib
Basic dosage, take once when limosis in the morning. If patients cannot suffer from AEs, they can get declined dosage.
Other Name: AL3818 |
Placebo Comparator: Placebo
Placebo p.o, qd and it should be continued until disease progress or patients withdraw consent
|
Drug: Placebo
Basic dosage, take once when limosis in the morning. |
- Overall Survival (OS) [ Time Frame: From randomization until death (up to 24 months) ]
- Progress free survival (PFS) [ Time Frame: each 42 days up to PD or death(up to 24 months) ]
- Objective Response Rate (ORR) [ Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months) ]
- Disease Control Rate (DCR) [ Time Frame: each 42 days up to intolerance the toxicity or PD (up to 24 months) ]
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: Until 30 day safety follow-up visit ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 75 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Signed and dated informed consent
- Diagnosed with advanced NSCLC (phase IIIB/IV) through pathology, with measurable nidus(using RECIST 1.1)
- at least two systematic chemotherapy with upwards of 3-line treatments or cannot suffer
- Patients must provide detectable specimen (from tumor tissue or hydrothorax) before participating, who negative in EGFR&ALK can participate or who positive in EGFR&ALK, have or have not drug tolerance after the treatment with relative targeted drugs
- ECOG PS:0-1,Expected Survival Time: Over 3 months
- main organs function is normal
- The woman patients of childbearing age who must agree to take contraceptive methods (e.g. intrauterine device, contraceptive pill or condom) during the research and within another 6 months after it; who are not in the lactation period and examined as negative in blood serum test or urine pregnancy test within 7 days before the research; The man patients who must agree to take contraceptive methods during the research and within another 6 months after it
Exclusion Criteria:
- have used Anlotinib before
- Small Cell Lung Cancer (including small cell cancer and other kinds of cancer mixed with non-small cell cancer)
- examined as positive in EGFR&ALK mutation detection and never take the treatment of TKIs
- central lung squamous carcinoma along with cavum, or non-small cell lung cancer along with hemoptysis (>50ml/day)
- other kinds of malignancies within 5 years or for now
- plan to take systemic anti-tumor therapy within 4 weeks before grouping or during the medicine-taking period of this research, including Cytotoxic Therapy, Signal Transduction Inhibitor, and Immunotherapy (or who use Mitomycin C within 6 weeks before taking the treatment with experimental drug); The patients who have already taken Extended Field Radiotherapy (EF-RT) within 4 weeks before grouping or Limited Field Radiotherapy with proposed assessment of nidus within 2 weeks before grouping
- have got non remissive toxic reactions derived from previous therapies, which is over level 1 in CTC AE (4.0), alopecia NOT included
- with kinds of factors which affect oral medicine (e.g. failing to swallow, gastrointestinal tract getting resected, chronic diarrhea and ileus)
- pleural effusion or ascites, resulting in respiratory syndrome (≥CTC AE level 2)
- symptoms of brain metastases cannot be controlled and treated within less than 2 months
- get any severe diseases or the ones that cannot be controlled
- take major surgical treatments, open biopsy, or get overt traumatic injury within 28 days before grouping
- have any habitus or medical history of hemorrhage, however severe it is; the patients who have non healing wounds, ulcer or fracture after any events with hemorrhage or bleeding (≥CTCAE level 3)
- get arterial/venous thrombosis within 6 months, such as cerebrovascular accidents (including temporary ischemic stoke), deevenous thrombosis, and pulmonary embolism
- ever abuse psychiatric drugs and cannot abstain or who are diagnosed with mental disorder
- have participated in other clinical trials of anti-tumor medicine within 4 weeks
- diagnosed with disease which will severely endanger the security of patients or influence the completion of this research.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02388919
Study Director: | Baohui Han, professor | Chest hospital affiliated to Shanghai jiaotong university | |
Study Director: | Kai Lee, professor | Tianjin Medical University Cancer Hospital |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. |
ClinicalTrials.gov Identifier: | NCT02388919 |
Other Study ID Numbers: |
ALTN-03-IIB |
First Posted: | March 17, 2015 Key Record Dates |
Last Update Posted: | September 18, 2017 |
Last Verified: | January 2017 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | Undecided |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Product Manufactured in and Exported from the U.S.: | No |
anlotinib Cancer NSCLC Non-small Cell Lung Cancer |
Lung Neoplasms Carcinoma, Non-Small-Cell Lung Respiratory Tract Neoplasms Thoracic Neoplasms Neoplasms by Site |
Neoplasms Lung Diseases Respiratory Tract Diseases Carcinoma, Bronchogenic Bronchial Neoplasms |